Previous 10 | Next 10 |
2024-03-06 08:24:28 ET More on Pre-market losers & stocks. Datasea jumps 23% as subsidiary enters a potential $30M sale agreement Seeking Alpha’s Quant Rating on BeyondSpring Historical earnings data for BeyondSpring Financial information for Beyon...
2024-03-06 07:23:30 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Transcript Vanda Pharmaceuticals: FDA Approvals On Deck In 2024 Ma...
2024-02-23 17:39:49 ET Gainers: Sizzle Acquisition ( SZZL ) +12% . ImmunityBio ( IBRX ) +6% . E.W. Scripps ( SSP ) +5% . Outset Medical ( OM ) +5% . BigCommerce Holdings. ( BIGC ) +5% . Losers: EverQuote...
2024-02-12 22:59:06 ET Summary Vanda Pharmaceuticals is trading materially below its holdings of cash and marketable securities (worth almost $7/share). Multiple FDA approvals, if forthcoming, in 2024 could prove to be material catalysts, perhaps highlighting that the company has ...
2024-02-07 17:51:05 ET Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Conference Call February 07, 2024 04:30 PM ET Company Participants Kevin Moran - Chief Financial Officer Mihael Polymeropoulos - President, Chief Executive Officer & Chairman Tim Willia...
2024-02-07 16:14:15 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: FDA Approvals On Deck In 2024 Makes This A Must Watch Vanda updates on FDA review for Hetlioz label expansion Fed court allows Vanda lawsuit against FDA to move forward Seeking Alpha&...
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire Full year 2023 revenues were $192.6 million PONVORY ® acquisition completed in Q4 2023 and transition ongoing 3 FDA PDUFA target action dates in 2024 ...
Penske Automotive Group Inc. (PAG) is expected to report $3.66 for Q4 2023 Copa Holdings S.A. Class A (CPA) is expected to report $3.9 for Q4 2023 Wynn Resorts Limited (WYNN) is expected to report $1.12 for Q4 2023 U-Haul Holding Co Com (UHAL) is expected to report $0.82 for Q3 2024 ...
2024-02-05 08:34:42 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: FDA Approvals On Deck In 2024 Makes This A Must Watch Vanda Pharmaceuticals Inc. (VNDA) Q3 2023 Earnings Call Transcript Fed court allows Vanda lawsuit against FDA to move forward Big...
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia PR Newswire WASHINGTON , Feb. 5, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on February 4, 2024 , i...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...